Advertisement
Singapore markets close in 1 hour 26 minutes

  • Straits Times Index

    3,287.27
    -5.86 (-0.18%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,289.76
    +88.49 (+0.51%)
     

  • FTSE 100

    8,087.98
    +47.60 (+0.59%)
     

  • Bitcoin USD

    64,244.47
    -2,520.80 (-3.78%)
     

  • CMC Crypto 200

    1,391.53
    +8.95 (+0.65%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,334.70
    -3.70 (-0.16%)
     

  • Crude Oil

    82.98
    +0.17 (+0.21%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,570.41
    -1.07 (-0.07%)
     

  • Jakarta Composite Index

    7,150.35
    -24.18 (-0.34%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Can Emergent BioSolutions Recover From Its Recent Blunders?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·2-min read

Emergent BioSolutions (NYSE: EBS) might disagree after its highly publicized COVID-19 vaccine manufacturing problems. In this Motley Fool Live video recorded on June 23, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not Emergent BioSolutions can recover from its recent blunders. Brian Orelli: Yes, they can fix the issues that they had with the manufacturing and get better management in there to make sure that they're following all the FDA rules and good manufacturing practices.

Continue reading